Table Graph
   

inhaled interferon - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 2.45 [0.21, 28.37]< 10%2 studies (2/-)23.8 %some concernnot evaluable moderatecrucial-
deaths 0.87 [0.16, 4.83]< 10%4 studies (4/-)56.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.50 [0.19, 1.33]< 10%2 studies (2/-)91.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.64 [0.98, 2.76]> 133%3 studies (3/-)96.9 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.11 [0.60, 7.41]> 165%3 studies (3/-)87.8 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.42 [1.70, 6.88]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.90 [1.07, 3.35]> 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.76 [1.10, 2.81]> 10%1 study (1/-)99.1 %NAnot evaluable important-
death or ventilation 0.38 [0.09, 1.63]< 10%1 study (1/-)90.3 %NAnot evaluable important-
hospital discharge 1.63 [0.61, 4.35]> 10%1 study (1/-)83.5 %NAnot evaluable important-
mechanical ventilation 0.52 [0.02, 15.78]< 10%1 study (1/-)64.5 %NAnot evaluable important-
viral clearance 2.90 [1.64, 5.14]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.74 [1.10, 2.75]> 10%1 study (1/-)99.1 %NAnot evaluable important-
viral clearance by day 14 0.38 [0.00, 46.74]> 198%3 studies (3/-)35.1 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.52 [1.55, 4.09]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
recovery 2.19 [1.03, 4.67]> 10%1 study (1/-)97.9 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.95 [0.02, 50.33]< 10%1 study (1/-)51.0 %NAnot evaluable important-
adverse events 1.68 [0.47, 5.97]< 10%1 study (1/-)21.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons